The current status of non-biopharma drug discovery

Drug Discovery World

Volumn 15, Issue 2, 2014, Pages 62-69

  Comley, John ^a  

^a HTStec Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE;

DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SCREENING; DRUG TARGETING; FUNDING; HUMAN; NEGLECTED DISEASE; NEOPLASM; PHENOTYPE; PROTEIN PROTEIN INTERACTION; SHORT SURVEY;

EID: 84899010611     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. Frye, S et al (2011). US academic drug discovery. Nature Rev. Drug Discov. 10:409-410.
2. Tralau-Stewart, C et al (2014). UK academic drug discovery. Nature Rev. Drug Discov. 13: 15-16.
3. Academic Outreach & Non-Profit Screening Trends 2014, published by HTStec Limited, Cambridge, UK, February 2014.
4. Wigglesworth, M (2013). AstraZeneca's Open Door; High Throughput Screening Collaborations and Open Innovation. Miptec, Basel 23-26 September 2013.